The efficacy of STIVARGA in 3rd-line mCRC has been proven in two phase 3 trials

  • The repeated use of chemotherapy (oral or intravenous) beyond the 2nd line in mCRC has not been clinically shown to have a survival benefit in any large, randomized study
  • Re-treatment with an anti-EGFR agent is not guideline-recommended

We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…